

PTO/SB/08A (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/658,947	
			Filing Date	9/9/2003	
			First Named Inventor	Semple et al.	
			Art Unit		
Examiner Name					
Attorney Docket Number	INEX.P-003-3				
Sheet	1	of	5		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
an		US- 3,993,754	11/23/1978	Rahman et al.	
an		US- 4,145,410	3/20/1979	Sears	
an		US- 4,224,179	9/23/1980	Schneider	
an		US- 4,235,871	11/25/1980	Papahadjopoulos et al.	
an		US- 4,401,796	8/30/1983	Itakura	
an		US- 4,458,066	7/3/1984	Caruthers et al.	
an		US- 4,500,707	2/19/1985	Caruthers et al.	
an		US- 4,522,803	6/11/1985	Lenk et al.	
an		US- 4,588,578	5/13/1986	Fountain et al.	
an		US- 5,013,556	5/7/1991	Woodie et al.	
an		US- 5,208,036	5/4/1993	Eppstein et al.	
an		US- 5,264,618	11/23/1993	Felgner et al.	
an		US- 5,264,423	11/23/1993	Cohen et al.	
an		US- 5,276,019	1/4/1994	Cohen et al.	
an		US- 5,279,833	1/18/1994	Rose	
an		US- 5,283,185	2/1/1994	Epand et al.	
an		US- 5,286,634	2/15/1994	Stadler et al.	
an		US- 5,356,633	10/18/1994	Woodie et al.	
an		US- 5,532,130	7/2/1996	Alul	
an		US- 5,552,155	9/3/1996	Bailey et al.	
an		US- 5,665,710	9/9/1997	Rahman et al.	
an		US- 5,885,613	3/23/1999	Holland et al.	
an		US- 5,976,567	11/2/1999	Wheeler et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code* -Number*- Kind Code* (if known)				
an		WO 00/62813 A2	10/26/2000	The University of British Columbia		
an		WO 96/10391 A1	4/11/1996	The University of British Columbia		
an		WO 96/10392 A1	4/11/1996	The University of British Columbia		
an		WO 96/40964 A2	12/19/1996	Inex Pharmaceuticals Corporation		

Examiner Signature		Date Considered	10/31/05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of US PTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (06-03)

Approved for use through 06/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	10/658,947
		Filing Date	9/9/2003
		First Named Inventor	Semple et al.
		Art Unit	
		Examiner Name	
Sheet	2	of	5
		Attorney Docket Number	INEX.P-003-3


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		AGRAWAL, Antisense oligonucleotides: towards clinical trials, Trends in Biotech., 1996, Page(s) 376-387, Volume 14	
am		ATKINSON ET AL., Solid-phase Synthesis of Oligodeoxyribonucleotides by the Phosphite-triester Method, Oligonucleotide Synthesis: A Practical Approach, 1984, Page(s) 35-81, Volume 3	
		BAILEY ET AL., Modulation of Membrane Fusion by Asymmetric Transbilayer Distributions of Amino Lipids, Biochem., 1994, Page(s) 12573-12580, Volume 33, Number 42	
gu		BEAUCAGE ET AL., Deoxynucleoside Phosphoramidites--A New Class of Key Intermediates for Deoxypolynucleotide Synthesis, Tetrahedron Letters, 1981, Page(s) 1859-1862, Volume 22, Number 20	
gu		BEHR, Synthetic Gene-Transfer Vectors, Acc. Chem. Res., 1993, Page(s) 274-278, Volume 26	
gu		BENNETT ET AL., Cationic Lipids Enhance Cellular Uptake and Activity of Phosphorothioate Antisense Oligonucleotides, Molecular Pharmacology, 1992, Page(s) 1023-1033, Volume 41, Number 6	
gu		BENNETT, Intracellular Delivery of Oligonucleotides with Cationic Liposomes, CRC Press, 1995, Page(s) 223-322, Number 14	
an		BRIGHAM ET AL., Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle, The American Journal of the Medical Sciences, 1989, Page(s) 278-281, Volume 298, Number 4	
an		CARUTHERS ET AL., New Methods for Synthesizing Deoxyligonucleotides, Genetic Engineering, 1982, Page(s) 1-17, Volume 4	
an		CULVER K. W., Gene Therapy: A Handbook for Physicians, Mary Ann Liebert, Inc., Publishers, New York, 1994, pp. 33-41	
an		DEWHIRST ET AL., Extravasation of Stealth Liposomes into Tumors: Direct Measurement of Accumulation and Vascular Permeability Using a Skin Flap Window Chamber, Eds. Lasic, 1995, Page(s) 127-137, Number 12	

Examiner Signature		Date Considered	10/31/05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). \* Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 06/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/658,947		
		Filing Date	9/9/2003		
		First Named Inventor	Sample et al.		
		Art Unit			
Sheet	3	of	5	Examiner Name	
				Attorney Docket Number	INEX.P-003-3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ju		FISKE ET AL., The Colorimetric Determination of Phosphorous, J. Biol. Chem., 1925, Page(s) 375-400, Volume 66, Number 2	
ju		FROEHLER ET AL., Synthesis of DNA via deoxynucleoside H-phosphonate intermediates, Nucleic Acids Research, 1986, Page(s) 5399-5407, Volume 14, Number 13	
ju		GALBRAITH ET AL., Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides, Antisense Research and Development, 1994, Page(s) 201-206, Volume 4, Number 3	
ju		GUO ET AL., Steric Stabilization of Fusogenic Liposomes by a Low-pH Sensitive PEG-Diortho Ester-Lipid Conjugate, Bioconjugate Chem., 2001, Page(s) 291-300, Volume 12	
ju		HYDE ET AL., Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy, Nature, 1993, Page(s) 250-256, Volume 362, Number 6417	
ju		JONES, Preparation of Protected Deoxyribonucleosides, Oligonucleotide Synthesis: A Practical Approach, 1984, Page(s) 23-34, Number 2	
ju		KUNKEL ET AL., Duchenne/Becker muscular dystrophy: A short overview of the gene, the protein, and current diagnostics, British Medical Bulletin, 1989, Page(s) 630-643, Volume 45, Number 3	
ju		MANNINO ET AL., Liposome Mediated Gene Transfer, Biotechniques, 1988, Page(s) 682-690, Volume 6, Number 7	
ju		MATTEUCCI ET AL., Synthesis of Deoxyoligonucleotides on a Polymer Support, J. Am. Chem. Soc., 1981 Page(s) 3185-3191, Volume 103	
ju		NICOLAU ET AL., Liposomes as Carriers of DNA, Crit. Rev. Ther. Drug Carrier Syst., Volume 6, Issue 3, 1989, pp. 239-271	
ju		SINHA ET AL., $\beta$ -Cyanoethyl N,N-Dialkylamino/N-Morpholinomono-chloro Phosphoramidites, New Phosphitylating Agents Facilitating Ease of Deprotection and Work-up of Synthesized Oligonucleotides, Tetrahedron Letters, 1983, Page(s) 5843-5846, Volume 24, Number 52	

Examiner Signature		Date Considered	10/31/05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Project of 1998, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
 Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete If Known	
		Application Number	10/658,947
(use as many sheets as necessary)		Filing Date	9/9/2003
		First Named Inventor	Sampe et al.
		Art Unit	
		Examiner Name	
Sheet	4	of	5
		Attorney Docket Number	INEX.P-003-3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
am		SINHA ET AL., Polymer support oligonucleotide synthesis XVIII: use of $\beta$ -cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product, Nucleic Acids Research, 1984, Page(s) 4539-4557, Volume 12, Number 11	
am		SPROAT ET AL., Solid-phase Synthesis of Oligodeoxyribonucleotides by the Phosphotriester Method, Oligonucleotide Synthesis: A Practical Approach, 1984, Page(s) 83-115, Volume 4	
am		STEIN ET AL., Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?, Science, 1993, Page(s) 1004-1012, Volume 261, Number 5124	
am		STEPKOWSKI ET AL., Blocking of Heart Allograft Rejection by Intercellular Adhesion Molecule-1 Antisense Oligonucleotides Alone or in Combination with Other Immunosuppressive Modalities, J. Immunol., 1994, Page(s) 5336-5346, Volume 153, Number 11	
am		STRAUBINGER ET AL., Liposomes as Carriers for Intracellular Delivery of Nucleic Acids, Methods in Enzymology, 1983, Page(s) 512-527, Volume 101	
am		THIERRY ET AL., Liposomal Delivery as a New Approach to Transport Antisense Oligonucleotides, Gene Regulation: Biology of Antisense RNA and DNA, 1992, Page(s) 147-161	
am		UHLMANN ET AL., Antisense: Chemical Modifications, Encyclopedia of Cancer, 1997, Page(s) 64-81, Volume X	
am		VLASSOV ET AL., Transport of oligonucleotides across natural and model membranes, Biochimica et Biophysica Acta, 1994, Page(s) 95-108, Volume 1197	
am		WU ET AL., Increased Microvascular Permeability Contributes to Preferential Accumulation of Stealth Liposomes in Tumor Tissue, Cancer Research, 1993, Page(s) 3765-3770, Volume 53, Number 16	
am		YUDA ET AL., Prolongation of Liposome Circulation Time by Various Derivatives of Polyethyleneglycols, Biol Pharm. Bull., 1996, Pages 1347-1351, Volume 19, No. 10	
am		ZELPHATI ET AL., Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes, Antisense Research and Development, 1993, Page(s) 323-338, Volume 3	

Examiner Signature		Date Considered	10/31/05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it displays a valid control number.

Substitute for form 1449B/PTO

Complete if Known

Application Number 10169 047

(use as many sheets as necessary)

Application Number	10/858,947
Filing Date	9/9/2003
First Named Inventor	Sample et al.
Art Unit	
Examiner Name	
Attorney Docket Number	INEX P-003-3

Sheet	5	of	3
-------	---	----	---

[illegible]

Examiner Signature		Date Considered	10/31/05
--------------------	---	-----------------	----------

Signature \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*